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Letter from the Director
Non-Hodgkin lymphoma is truly a success story. Through
cooperative research, survival rates have improved by more
than 40 percent since the 1970s. In fact, cure rates for all
types of childhood cancers have also improved. From 1975-77,
survival rates for all types of childhood cancers combined was
58 percent. Today, overall survival rates are greater than 80
percent for all childhood cancers.

Alan Gamis, MD
Associate Division
Director,
Section of Oncology
Professor of Pediatrics,
University of MissouriKansas City School of
Medicine

Because childhood cancer is relatively rare, physicians and
scientists have had to join forces to achieve the excellent cure
rates we see today. The doctors and nurses at Children’s Mercy
are members of the Children’s Oncology Group, the largest
international research consortium. As a large childhood cancer
center within the COG, Children’s Mercy sees approximately
180 new oncology patients each year, while following an
additional 1,500 patients during and after treatment. And, we
are currently participating in 80-100 clinical trials at any given
time.
The Division of Pediatric Hematology/Oncology/Bone Marrow
Transplantation at Children’s Mercy has seen some amazing
changes in the past few years. We have grown from five
Pediatric Hematologists/Oncologists in 1995 to a current staff
of 22 physicians. With this incredible growth, we have been
able to create a dedicated Leukemia/Lymphoma program. This
program, led by Keith August, MD, allows us to bring together a
group of providers that are focused on administering the latest
and best care for patients with leukemia and lymphoma.
We continue to expand our Experimental Therapeutics in
Pediatric Cancer Program. This program brings novel therapies

to our relapsed or refractory patients and currently has 15
open protocols. In addition, we are expanding our inpatient unit
by opening a new Bone Marrow Transplant Unit with 15 beds,
making a total of 38 beds dedicated to our patients. With
Magnet recognition and specially trained pediatric oncology
nurses, we provide excellent inpatient care.
Successful treatment of childhood cancer does not end with
curing the patient. Childhood cancer survivors need specialized
care even after they have been cured of their disease. To this
end, Children’s Mercy has developed a Survive and Thrive Clinic,
led by Joy Fulbright, MD, and coordinated by nurse Wendy
McClellan, to help survivors with late effects and to ease the
transition from pediatric care to the adult health care setting.
This report focuses on non-Hodgkin lymphoma, a cancer that,
while it may often present as a medical emergency, is now
highly curable through the availability of our multidisciplinary
team for accurate diagnosis, staging, treatment and supportive
care.
We also use this report to highlight other aspects of our
Hematology/Oncology Division, which is proud to be ranked by
U.S. News and World Report as one of the top comprehensive
children’s cancer centers in the nation. We hope to highlight
some of the many ways we are working wonders to help treat
and cure childhood cancer.

Letter from the President and CEO
Dear Friends,
Few things tug at the heart as strongly as the thought of
children with cancer.
We are fortunate at Children’s Mercy to have one of the
leading programs in the country to help children and their
families cope with this devastating disease. Our team of
physicians, nurses, support staff and researchers are
committed to providing the highest level of care to these
families, while also working toward improving treatments and
finding cures for childhood cancers.
Our Experimental Therapeutics in Cancer program continues
to grow and achieve national prominence. Working in
collaboration with national consortia, we are utilizing our
world-renowned pediatric clinical pharmacology expertise to
make cancer medications safer and more effective for children
here and around the world.
In addition, our Hematology/Oncology staff is leading
innovative research to better understand cancers such as
mixed lineage leukemia (MLL) and improving how patients
respond to bone marrow transplants. We continue to expand
services for children with liver tumors, brain tumors and other
types of childhood cancers.

We treat nearly 90 percent of all newly diagnosed pediatric
cancers in our region, and our outcomes rank among the best
in the nation. Through our Adolescent and Young Adult
program, highlighted in this report, we are now working to
extend that same success to older teens and young adults
who could benefit from the same aggressive treatments and
protocols.
We are pleased to note that many of the efforts highlighted in
the follow pages are collaborative, in particular, our role in the
KU Cancer Center. We are committed to working with others to
advance pediatric medicine and do whatever it takes to help
improve the health and well-being of children here and around
the world.
It is no wonder we are ranked by U.S. News and World Report
as having one of the best children’s cancer programs in the
country. As highlighted by the patient success stories in this
report, our Hematology/Oncology staff is working wonders
every day.

Randall L. O’Donnell, PhD
President and CEO
Children’s Mercy
Hospitals and Clinics

Sincerely,
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The Division of Hematology/Oncology/Bone Marrow Transplantation
Children’s Mercy is the region’s leading pediatric cancer program, caring for nearly 90 percent of new pediatric
cancer diagnoses in the area. We offer 10 times more pediatric cancer specialists than any other hospital
between St. Louis and Denver. Our unique case management system provides every patient with the highest
level of care throughout the course of their disease. Plus, our role in several national research consortia helps
make sure your patients have access to the most recent advances in treatment.
ii We operate one of the larger childhood cancer centers in the country, with 22 pediatric specialists on
staff, and have received Accreditation with Commendation from the American College of Surgeons
Commission on Cancer.
ii Our survival rates for nearly every type of cancer we treat are at or above national averages.
ii Your patients have direct access to more than 80 pediatric clinical trials — including several national
trials led by our own investigators, as well as trials through the National Cancer Institute’s Children’s
Oncology Group and several other national research consortia.
ii Our Experimental Therapeutics in Pediatric Cancer program, working with our internationally recognized
Clinical Pharmacology program, is helping make cancer treatment safer and more effective for children
here and around the world.
ii As the primary pediatric cancer provider and only NCI Children’s Oncology Group institution in the Midwest
Cancer Alliance, we were instrumental in bringing National Cancer Institute designation to the region.
ii We are the only accredited pediatric cancer program by the American College of Surgeons Commission
on Cancer in the region and the only pediatric cancer program to have received the “Outstanding
Achievement Award” from this organization in the past two three-year survey cycles.
ii Our pediatric bone marrow transplantation program is a regional center for Missouri, Kansas and Iowa,
performing 35 transplants a year, including unrelated and related donor transplants for both malignant
and non-malignant diseases.

6

7

Cancer Registry
Cancer registrations begin with the identification of patients who have been diagnosed
or treated for malignancies, or other certain benign/borderline conditions, at Children’s
Mercy or other clinics. The Cancer Registry is operated under the guidance of the Cancer
Care Committee and maintains the data standard requirements of the American College
of Surgeons Commission on Cancer and the State of Missouri. A complete summary of
the data elements concerning diagnosis, histology, site, treatment and disease status
is captured. The patients are also followed annually to evaluate treatment methods,
outcomes and other patient needs. By having access to such data the impact of disease
can be analyzed at Children’s Mercy and also at the state and national levels.
2011 Registry Statistics
Numbers: During 2011, there were 185 patients added to the Registry database.
Central Nervous System tumors represented 26 percent of the annual caseload with
leukemia close behind at 23 percent. There were 13 benign reportable conditions that
are required by the cancer care committee to be collected due to propensity to recur and
special interest. Please see the frequency table for further breakdown of disease types.
Age at Diagnosis: There were 26 patients less than 1 year of age diagnosed during
2011. The 1-4 age group consisted of 57 patients, the 5-9 age group had 29 patients,
the 10-14 age group had 40 patients, and there were 33 patients in the 15-19 age range.
Sex: There were 97 female patients and 88 male patients during 2011.
Analytic Patients: During 2011, there were 165 analytic patients, who are patients
diagnosed at Children’s Mercy or elsewhere but received all of their first course of
treatment at Children’s Mercy. The analytic patients are those eligible for inclusion in the
registry’s statistical reports of treatment efficacy and survival.
Race: There were 149 Caucasians, 25 African Americans and 11 Other races. Within the
149 Caucasian patients, 18 were of Spanish/Hispanic ethnicity.
Geographic Origin: During 2011, our cancer patients came from four different states and
48 different counties. Fifty-one percent of the patients were from Missouri, 48 percent
from Kansas and 1 percent from other states.
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Maxine Hetherington, MD

Non-Hodgkin Lymphoma Subtypes and Subgroups

Totals Percentage

Central Nervous System

49

Astrocytoma

13

Glioma

9

Ependymoma

4

PNET

2

Medulloblastoma

1

Germ Cell

1

Gliobastoma Multiforme

1

Benign/Borderline CNS

18

Leukemia

42

Acute Lymphoblastic Leukemia (ALL)

33

Acute Myelogenous Leukemia (AML)

9

26%

23%

Lymphoma

15

8%

Non-Hodgkin

9

Hodgkin

6

Neuroblastoma

8

4%

Ewing’s Family of Tumors

6

3%

Rhabdomyosarcoma

6

3%

Wilms Tumor

6

3%

Langerhans Histiocystosis

12

7%

Osteosarcoma

8

4%

Retinoblastoma

2

1%

Hepatoblastoma

3

2%

Carcinomas

5

3%

Other Malignant Conditions

10

6%

Benign Reportable Conditions

13

7%

Non-Hodgkin Lymphoma Overall Five Year Survival of Subgroups

2002-2011 - Total= 64
Anaplastic Large Cell-n=9,OS=100%
Burkitt’s Cell Type-n=30, OS=100%

Percent Survival

Frequency by Diagnosis 2011

Diffuse Large B Cell-n=12, OS=83%
Lymphoblastic Type-n=13, OS=73%

Anaplastic Large Cell Lymphoma
Burkitt’s Lymphoma
Diffuse Large B Cell Lymphoma
Lymphoblastic Lymphoma

0

TOTAL

185

100%

1

2

3

4

5

Years
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Staying Positive on the Field—and Against a Daunting Illness
McKenzie Haynes isn’t an athlete who puts up with
losing. So, in 2010, when the Salina, Kan., high
school sophomore earned an admirable eighth place
in the 5A state tennis tournament, she made it a
priority to finish even better the next year. And, when
the threat of leukemia entered her court and threw
a wrench in her plans? McKenzie simply shifted her
focus from beating her tennis rivals to beating the
disease.
McKenzie’s superior athleticism was an initial
indicator that something wasn’t right as the sports
seasons evolved that winter. Unusually short
of breath for an athlete who excelled at nearly
every sport she attempted, McKenzie was initially
diagnosed with asthma. Blood tests, however, later
proved the condition was much more serious:
refractory anemia with excess blasts Type I, a
potentially life-threatening illness that can lead to
leukemia.
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realize there are things more important than sports
and school and all that kind of stuff.”
Maintaining that positive attitude led to McKenzie
getting back on the court less than 60 days after
leaving the hospital. Within eight months of her first,
tentative practice strokes, she was ready for the
tennis season to start. And by tournament time?
McKenzie was once again in top form. With her
partner by her side, she placed fourth in the state.
Today, she’s considering scholarship opportunities to
determine where she’ll attend college in the fall.
Her physician at Children’s Mercy, Jignesh Dalal, MD,
Associate Division Director, Section of Bone Marrow
Transplantation, called her recovery “amazing.” He
cited her strong positive attitude as a significant
factor in putting her back at the top of her game –
both literally and figuratively.
In fact, “All bone marrow transplant patients should
follow her lead,” he said.

Treatment at Children’s Mercy Hospital included
blood transfusions, chemotherapy and an eventual
bone-marrow transplant. Despite those challenges,
McKenzie’s positive attitude and competitive spirit
never wavered. In fact, McKenzie cited the illness for
making her “a lot stronger.”

“You need to do what you need to do,” he said,
referring to the various treatments such serious
illnesses require. “But, then, once it is done, move
on. Move on with your life. Be positive. Don’t let the
past affect your present,” he emphasized.

“It made me realize that all the little things aren’t
such a big deal,” she said. “You take a step back and

Or, in McKenzie’s case, take advantage of your past
to make you stronger for the future.
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Karen Lewing, MD

Non-Hodgkin Lymphoma
Non--Hodgkin lymphoma (NHL) is a diverse group of
malignancies originating from cells of the immune system.
NHL is tied with Hodgkin lymphoma as the sixth most common
type of cancer in children aged infant to 14, accounting for 4
percent of cancers in this age group. The annual incidence
is 1.3 cases per 100,000 children in this age group, and 1.8
cases per 100,000 children, ages 15-19. A disproportionately
high incidence is seen in males, with a male to female ratio of
3:1.
1

2

2

As opposed to the typical low or intermediate grade lymphoma
seen in adults, nearly all childhood lymphomas are high grade.
Four types of NHL are routinely seen in children:
ii Burkitt’s lymphoma, (BL, formerly small, non-cleaved cell
lymphoma [SNCCL])
ii lymphoblastic lymphoma (formerly precursor T-cell
lymphoblastic lymphoma, [T-LL])
ii diffuse large B-cell lymphoma (DLBCL)
ii anaplastic large cell lymphoma (ALCL)
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Although the etiology of NHL is unknown, suppression of the immune
system has been related to the development of NHL in some patients.
Children with inherited (Wiskott-Aldrich, X-linked agammaglobulinemia,
ataxia-telangiectasia) and acquired (EBV infection, HIV infection)
immunodeficiencies are at increased risk for developing NHL. Lymphoma
cells are believed to arise from a single damaged cell, with genetic
mutations that influence cell growth, differentiation and/or cell death.

Clinical Presentation
NHLs may present in various ways, depending on the subtype.
In general, patients with NHL present with enlarged lymph nodes and may
have systemic symptoms such as fever, fatigue or weight loss. Typical sites
of disease include the abdomen for BL and mediastinum for T-LL.
NHL often has a much more sudden onset than HL or adult types of NHL.
This is a result of rapid growth of the cancer cells, which are typically higher
grade tumors in childhood. Because of the propensity for rapid growth,
children with NHL are more likely to present with emergent complications
than any other tumor type.
Complications may include airway compression from a mass in the
chest, obstruction of the bowel from abdominal masses and metabolic
derangements from rapid cell turnover.

Work-Up
Evaluation of the patient with suspected NHL includes baseline laboratory
work to assess renal function, liver function, coagulation and hematologic
status. A chest X-ray should be performed prior to any procedures to
evaluate for a mediastinal mass. CT scans are often the initial imaging
study to identify the sites of disease. Positron emission tomography (PET)
scans have gradually replaced gallium scans and are now considered
an essential tool in the initial evaluation of patients with NHL. Whenever
clinically feasible, an incisional lymph node biopsy is recommended to make

the diagnosis. Fine needle aspirations are not recommended, as they do
not provide adequate tissue for accurate subtyping. If the patient is critically
ill, alternative methods of diagnosis may be needed, such as sampling of
pleural effusions. Additional diagnostic tests, such as bone marrow exams
or lumbar punctures, are typically needed to complete the work-up.

Surgery
The role of the surgeon in the treatment of NHL is generally relatively
limited. Initial incisional biopsy for diagnosis is usually required. In children
with rapidly progressing lesions such as Burkitt’s lymphoma, this can
assume some urgency. The next step is often multi-agent chemotherapy,
with the exception of small, easily resectable lesions.
Even initial biopsy can be challenging in children with extensive thoracic
and mediastinal disease, in whom induction of general anesthesia and the
attendant loss of airway tone in conjunction with myocardial depression may
result in catastrophic respiratory or circulatory collapse. The most common
tumor type with mediastinal involvement is usually lymphoblastic lymphoma.
Alternative diagnostic techniques (needle biopsy by interventional radiology,
local anesthesia) may be helpful. Rarely, treatment must be instituted
presumptively prior to diagnosis.
Generally, tumor burden is the most important prognostic factor in
predicting outcome, and there is no role for aggressive attempts at primary
resection. However, in disease that can be easily and completely resected,
it may improve EFS and prevent complications.
Transplant surgeons may be involved in the care of their patients who
develop Post-Transplant Lymphoproliferative Disorders (PTLD). The risk of
developing this disorder after solid organ transplantation (TP) depends on
the type of transplant (renal TP is the lowest risk, heart-lung TP the highest)
and the intensity and duration of immunosuppression. EBV seronegative
patients and young age at TP are risk factors.
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Staging
The well-established St. Jude’s Staging System is utilized for
patients with NHL. Approximately 60 percent of children with NHL
will present with advanced stages of disease (III or IV).

Pathogenesis and Pathology
The diagnosis of NHL requires biopsy of involved sites. Biopsy
samples are submitted to pathology, examined and samples of the
biopsy are routinely submitted for light microscopy, flow cytometric
immunophenotyping, cytogenetic testing and molecular genetic
analysis. Additional portions of the biopsy sample may be frozen
for potential treatment or research related studies. Results from
all the studies confirm the diagnosis, establish the subtype of NHL,
and provide useful cytogenetic and molecular genetic information
for establishing prognosis and guiding therapy.
Childhood NHLs are sub-classified on the basis of size and pattern
of cells under the microscope to distinguish them from Hodgkin
lymphomas and type them as Burkitt’s lymphoma, lymphoblastic
lymphoma or one of several types of large cell lymphomas.
The most frequent large cell NHL is Anaplastic Large Cell
Lymphoma. Accurate subtyping often requires the use of ancillary
testing and special immunohistochemical stains to establish T or B
lymphocyte lineage and the particular stage of maturation. Though
any one of these types of lymphomas may occur in adults, they are
much more common in children and have a distinctly different
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prognosis and treatment strategy. The types of NHLs also differ
from adult lymphomas in that they are more aggressive, more
frequently arise in extra nodal site such as abdominal mesentery or
mediastinum, proliferate extremely rapidly and are often associated
with systemic symptoms.

Genetics & Molecular Biology
The genetic changes that occur in the lymphoma cells help to
establish the sub-type of the lymphoma. Commonly, the tissue sent
to the cytogenetics lab is broken up and put into tissue culture to
encourage cell growth. Usually the cells are ‘harvested’ the next
day. Dividing cells show the chromosomes of the lymphoma.
Genetic changes that characterize lymphoma can be seen by
looking at all the chromosomes in a cell using a microscope. Often
the genetic changes are specific to the diagnostic subtype of
lymphoma.
Fluorescence in situ hybridization analysis (FISH) is another
way to examine the involved tissue to look for specific genetic
changes that can contribute to the diagnosis. FISH uses small
pieces of DNA specific to a gene. These DNA pieces are tagged
with color that can be seen under the microscope. The pieces are
very specific and can be used to confirm that a particular gene is
affected in the lymphoma.

St. Jude’s (Murphy) Staging System
for Childhood Non-Hodgkin Lymphoma
Stage

Definition

I

Single tumor (extranodal) or single
anatomic area (nodal), excluding
mediastinum or abdomen

II

Single tumor (extranodal) with
regional node involvement
On same side of diaphragm:
a) Two or more nodal areas
b) Two single (extranodal) tumors
with or without regional node
involvement
Primary gastrointestinal tract tumor
(usually ileocecal) with or without
associated mesenteric node
involvement, grossly completely
resected

III

On both sides of diaphragm:
a) Two single tumors (extranodal)
b) Two or more nodal areas
All primary intrathoracic tumors
(mediastinal, pleural, thymic)
All extensive primary intra-abdominal
disease; unresectable
All primary paraspinal or epidural
tumors regardless of other sites

IV

Any of the above with initial central
nervous system or bone marrow
involvement (<25 percent)
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Treatment
Substantial progress has been made in treating NHL. Five-year
relative survival rates for children with NHL have improved from 43
percent in 1975-77 to 86 percent survival rates in 2001-2007.
Patients with localized disease will typically have survival rates
exceeding 90-95 percent. Historically, treatment regimens have
been focused on intensifying therapy to improve cure rates. With
improved outcomes, more recent trials are attempting to reduce
therapy in certain subgroups of NHL patients, in attempts to reduce
toxicities.
1

NHLs, with their propensity for rapid growth, are very chemosensitive. Therefore, chemotherapy is the major modality used in
treating NHL. The excellent cure rates we see today are the result
of many cooperative trials and improvements in diagnosis and
supportive care. A variety of chemotherapy regimens are used,
which are highly dependent on the subtype of NHL. Length of
therapy also varies greatly between subtypes. Treatment of BL or
DLBCL is typically short and intense (approximately six months
in length) as compared to T-LL where chemotherapy is given for
approximately two years. Radiation is rarely needed in the initial
treatment of NHL. As previously noted, surgery’s critical role is in
obtaining tissue at diagnosis.
While outcomes have improved dramatically over the years, there is
still room for improvement. Novel therapies are being evaluated

References

16

to treat refractory or relapsed patients. These therapies include
targeted therapies, such as antibodies, where the goal is for the
medication to attack the tumor cells more specifically and cause
less harm to the surrounding normal tissues.
Treatment of the patient with NHL requires the expertise and
collaboration of the surgeon, radiologist, pathologist, cytogeneticist
and pediatric oncologist to achieve such excellent outcomes. By
participating in collaborative trials, oncologists at Children’s Mercy
continue to help improve the outcomes for patients with NHL. In
addition, patients with NHL need long-term care and evaluation for
late effects or side effects caused by the treatments used in NHL.
With the development of our Survive and Thrive Clinic, Children’s
Mercy has a dedicated group of providers that are specifically
trained in monitoring and treating late effects.

Children’s Mercy Outcomes
From 2001-2010, 64 patients have been diagnosed with NHL at
Children’s Mercy, with a mean of 6.4 new cases/year for the past
10 years. Overall survival is 89.7 percent with a median follow-up
of 225 weeks. The male:female ratio is 2.4 : 1.0. Overall survival
of patients at Children’s Mercy is compared to national data in the
adjacent graphs. Children’s Mercy survival (89.7 percent) compares
favorably to national results (86 percent survival).

1.

Siegel R., Naishadham D., Jemal A.: Cancer Statistics, 2012. CA: A Cancer Journal for Clinicians 2012; 62: 10-29.

2.

Seer Data: Howlader N, Noone AM, Krapcho M, (eds) et al.: SEER Cancer Statistics Review, 1975-2009 (Vintage
2009 Populations), National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2009_pops09/,
based on November 2011 SEER data submission, posted to the SEER website, 2012.

Non-Hodgkin Lymphoma Survival Rate Comparison
Tristan Flatt, DO

Children’s Mercy Hospital (CMH) vs Surveillance Epidemiology and End Results (SEER)
of the National Cancer Institute

17

A High School Routine Interrupted Twice
The local doctor thought Josh Carroll’s “crumminess”
might be attributed to pancreatitis. So, as the Lamar,
Mo., teenager’s condition at Barton County Memorial
Hospital continued to get worse throughout that first
week he was there, he was transferred to Children’s
Mercy Hospitals and Clinics for further testing.
Josh entered Children’s Mercy as a Gastroenterology
patient on Dec. 20, 2009. And, on the morning of Jan.
1, 2010, he was officially diagnosed with non-Hodgkin
lymphoma.

This time, the tumor was growing on Josh’s spine,
which explained the paralysis. For three weeks, he
couldn’t move and the family didn’t know if Josh
would ever walk again. Dr. Lewing asked for a more
aggressive treatment protocol and Josh didn’t leave
the hospital for 70 days as he fought the cancer for
the second time.

“The suspected pancreatitis was eventually part of it,”
says Josh. “I actually had a cancerous tumor in my
pancreas.”

Through the chemotherapy treatment, Josh slowly
regained feeling in his lower half. And, working with
the Occupational Therapy and Physical Therapy
Departments at Children’s Mercy, he began to walk
again.

Immediately, Josh began treatment in the Children’s
Mercy Division of Hematology/Oncology/Bone
Marrow Transplantation. Assigned to Karen Lewing,
MD, Pediatric Hematologist/Oncologist and an
Assistant Professor of Pediatrics at the UMKC School
of Medicine, Josh continued treatments through April
2010.

“He basically missed his entire junior year as he
worked his way back and through chemotherapy,”
adds Phillip, admitting that the relapse was hard for
the entire family. But, turning to Dr. Lewing and their
cancer team at Children’s Mercy, Josh and his family
found the support and expertise they needed to get
through the aggressive treatment plan.

“At that time, we thought we were past it,” adds Phillip
Carroll, Josh’s father.
Unfortunately, Josh relapsed on Aug. 25, 2010, just
four months later. It was the summer before his junior
year of high school.
“I woke up paralyzed from the waist down at 4 a.m. –
just couldn’t move,” says Josh, adding that he was
then life flighted back to Children’s Mercy, where the
Carroll family learned that the cancer was back.
18

“Not again,” he remembers thinking that day.

After the second long bout of treatment, Josh was
again declared cancer-free, joining his high school
classmates to attend prom in the spring of 2011 and
graduating the following year.
Now, Josh is in his first year at Pittsburg State
University in Pittsburg, Kan., and, because of his
experiences with Children’s Mercy, he has plans to
study pre-medicine in hopes of becoming a doctor.

Karen Lewing, MD
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Nutrition
Supportive therapy for non--Hodgkin lymphomas often requires early intervention by
nutritionists. Pain and limited stomach capacity from rapidly growing abdominal tumors
often render patients acutely malnourished at diagnosis, as they’re simply unable to eat
anything until the tumor can be reduced.
This is typically a medically and emotionally intense time period requiring rapid
interventions and frequent interruptions in eating/feeding which further compromise
nutritional status. Once treatment is initiated lymphomas can shrink rapidly, which
can help relieve some pain and stomach compression. Initially the large amount of
destroyed lymphoma cells can overwhelm vital organs, making the child extremely ill,
which further complicates feeding.
Early interventions with tube feedings or IV nutrition are often not an option due to
medical complexity. Once the child’s tumor burden is reduced and vital functions
stabilized, nutrition therapy focuses on support with tube feedings or IV nutrition until
appetite returns after chemotherapy. However, the intensive treatment schedules
required for NHL can damage the stomach and intestinal lining as well as cause
significant nausea, continuing to render the child unable to meet their needs by eating.
Feeding tubes are often used to deliver consistent nutrition until side effects decrease.
Developments in supportive medications and nutrients have improved children’s
recovery time after chemotherapy, allowing them to eat naturally with the support of their
families and medical team. Nutrients targeted to support the stomach and intestines
at the cellular level can increase resilience to chemotherapy damage, which allows for
shorter recovery time after chemotherapy. Medications to stimulate a child’s appetite
often help reduce the amount of time they require supportive nutrition, allowing them to
eat naturally which is a significant emotional comfort to the child and their family.
Registered dietitians specializing in nutrition, support and assess children with NHL daily
while in the hospital, recommending adjustments to feeding regimens and IV nutrition
prescriptions. Once out of the hospital, dietitians continue to work with the child and
parents on transitioning to a diet high in calories, protein and food-derived vitamins and
minerals to improve quality of life and intestinal health.
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Radiology
Although tissue sampling is still required to make a diagnosis
of the non-Hodgkin lymphomas, imaging plays a vital role in
the workup, staging and monitoring of this disease.

PET/CT may also be useful in the localization of a site for
biopsy ensuring adequate tissue is obtained in a manner least
invasive to the patient.

Chest X-rays, abdominal ultrasounds, Computerized
Tomography (CT) scans of the chest and abdomen, and
Magnetic Resonance Imaging (MRIs) are all valuable
modalities used to evaluate and follow this disease. Crosssectional imaging (CT/MR) serves as the primary way of
determining the distribution, severity and staging of the
disease. In recent years, PET/CT has become a workhorse
for evaluation of NHL because of its ability to not only
detect tumor sites, but also to see if they are metabolically
functional.

Although not always appreciated, there is the radiation risk
associated with the ongoing use of diagnostic imaging.
During treatment and for several years afterward, imaging is
performed to detect disease recurrence, disease progression
and development of second malignancies. Although small,
the long-term risks of exposure to medical radiation are real.
One of the primary roles of the pediatric radiologist is to keep
radiation dose to a minimum in these patients, whose tissues
are not only more radiosensitive, but are getting more CT
scans than other children.

Positron emission tomography (PET) works by attaching a
radioactive particle to glucose, which is then taken up by the
metabolically active tissue. This modality is particularly useful
on post treatment examinations when a residual mass may
persist, but may not represent active disease. The anatomical
(CT) and functional (PET) components are performed at the
same time, and by fusing them together it can show if certain
areas are active tumor or just residual soft tissue mass.

At Children’s Mercy, we work hard to ensure the children
who receive diagnostic imaging receive the lowest amount
of radiation necessary to provide the needed results. With
state of the art equipment, special pediatric dose calculators,
certified technologists and board certified pediatric
radiologists, we are proud to work with the excellent team of
providers at Children’s Mercy to provide optimal care for the
children with non--Hodgkin lymphoma.
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Inpatient Unit

Outpatient Clinic

The course of treatment for a pediatric oncology patient of
any age, and with any cancer diagnosis, includes an inpatient
hospital stay.

The Hematology/Oncology Clinic provides a multi-disciplinary
approach in caring for all oncology patients, including the
non--Hodgkin lymphoma patients and their families.

While a patient is in the hospital undergoing treatment, the
cancer care team works to make the child and family’s
transition to daily hospital life as seamless as possible. The
nurses that staff the Hematology/Oncology/Bone Marrow
Transplantation Unit are typically the front line of daily care for
the patient and family.

The clinic includes experienced, highly skilled registered
nurses, many of whom are certified pediatric oncology
nurses. Nursing staff provides a vast range of nursing
services including coordination of patient care, assessment,
obtaining laboratory specimens, chemotherapy, biotherapy,
medication administration, sedations and transfusions
in a safe and nurturing environment. Patients and their
families are treated in the Hematology/Oncology Clinic with
compassion in a family-centered environment that recognizes
their physical, emotional, spiritual and social needs. The
clinic nurse advocates and provides support to patients
and their families during their treatment of non--Hodgkin
lymphoma through answering of questions, listening to their
concerns, and educating about medications and their side
effects.

These inpatient nurses are at the bedside administering
chemotherapy as well as other supportive medications to
handle the effects of the treatment. Aside from chemotherapy,
the nurses also assist with surgical biopsies or removal
of the lymph nodes, as well as procedures that require
sedations, such as lumbar punctures that can be done on the
floor.
Clinical work aside, inpatient nurses are provided more
resources and education to assist families at the time of
diagnosis. While the physicians and residents are responsible
for all aspects of diagnosis, nursing input is welcome and
valued. It is usually the inpatient nurse’s responsibility to
coordinate care between the multi-disciplinary care teams.
Inpatient nurses also alert the care team to changes
in patient status and assist the social workers with
psychosocial care during a stressful time.
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Joy Bartholomew,
APRN, MSN, CPON

Advanced Practice Nurses
Advanced practice nurses (APN) are very involved in the care of the patient with
lymphoma. APNs are master’s prepared nurses who partner with the patient’s
physician to provide individualized care.
This team approach allows for consistent providers for the patient and family as they
go through therapy, as well as follow up when the treatment is complete.
APNs provide case management services which encompasses the patients total
therapy needs. Patients with lymphoma often require specific labs, chemotherapy,
radiology imaging and therapy, inpatient and outpatient treatments, and home health
care. All of these needs are well coordinated for the patient with lymphoma by their
specific APN.
The APN provides education on the diagnoses of lymphoma and the treatment.
She will review the therapy and how it is affecting the patient, perform physical
examinations, order laboratory tests and scans, and prescribe medications. They
are the point person for phone contact when families are home and have questions
or problems. APNs provide support, guidance, education and help to determine
interventions that might lessen symptoms and make treatment as easy as possible.
We also have APNs that manage the inpatient chemotherapy service. These APNs
oversee the care of patients admitted to the hospital to receive chemotherapy. They
see the patients in the morning, do physical exams, adjust medications and then will
round on the patient with a physician each day. They are able to provide continuity of
care for these patients who are frequently hospitalized.
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Finding the Support When Your World is Upside Down
Surreal.
That’s the first word that comes to mind for Sarah
Martinez when she remembers back to her feelings
on Jan. 5, 2010 – the day she found out her 4-yearold son, Jude, had cancer.
“The Monday prior to diagnosis his left eyelid was
swollen, but there was no sign of infection,” says
Martinez, adding that Jude had tumbled down the
basement stairs of their Lee’s Summit, Mo., home a
week prior. “We took him into Children’s Mercy South
for an X-ray and they ended up doing a CT scan.
That’s when they found the primary tumor.”
When the results came back, Jude was diagnosed
with stage IV Burkitt’s lymphoma, an aggressive type
of non-Hodgkin lymphoma (NHL).
“My first reaction was to whisk him off to St. Jude’s,”
admits Martinez. “But, after meeting Dr. Lewing, my
husband and I knew that Children’s Mercy would be
the best place.”

“It’s a very aggressive cancer, so we did not have
the luxury of time,” added Martinez. “Thankfully, we
had faith in Dr. Lewing and Jude’s team with this
treatment plan.”
In addition to Dr. Lewing, Jude’s cancer care team
included Jill Anderson, APRN, CPHON, as well as
several other oncology nurses and staff members
dedicated to his care and treatment.
“When you are faced with losing the most precious
thing you have, you are in an indescribable state
of mind,” says Martinez. “But, because the staff
members at Children’s Mercy are part of your team,
they have the amazing ability to help you stay sane
and get you through every rough patch.”
After nearly seven months of the intense chemo,
Jude finished his treatment more than two years
ago. Now, a happy, witty, 7-year-old, Jude only visits
the Children’s Mercy Oncology Clinic for follow-up
appointments every four months.

“You know you have an amazing team and hospital
Karen Lewing, MD, pediatric hematologist/oncologist
when your son, who had just been through so much,
at Children’s Mercy and Assistant Professor of
is sad after finishing treatment because he wants to
Pediatrics at the UMKC School of Medicine, began an
still be on 4 Henson (inpatient unit),” adds Martinez.
intensive treatment plan that included the addition
“I also knew that his team was amazing when I had to
of a prescription drug known as rituximab as part of
adjust to not seeing them all of the time, too.”
Jude’s chemotherapy.
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Erin Guest, MD

Understanding the Role of the
MLL Gene in Infant Leukemia
The mixed lineage leukemia gene (MLL) is important in
human development. It is also a major contributor to the
development of infant leukemia. A physician researcher at
Children’s Mercy wants to know why.
“Our laboratory is especially interested in the MLL gene,” says
Erin Guest, MD, assistant professor of Pediatric Hematology
and Oncology at Children’s Mercy. “In some types of leukemia
this gene is broken and a piece of it gets attached to other
genes. This is extremely common in infant leukemia, where
over 80 percent of the babies with leukemia will have this MLL
translocation.”
Dr. Guest and Ali Shilatifard, PhD, from Stowers Institute
for Medical Research, are looking at interactions between
proteins and DNA in the nucleus of the cell. These proteins
are what tells the DNA which genes should be turned on and
which should be turned off.

get to know: Erin Guest, MD
Hematology/Oncology; Assistant
Professor of Pediatrics, University of
Missouri–Kansas City School of Medicine
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Just understanding the genetic code may not
be enough to really know exactly what makes
leukemia tick. Dr. Guest is also working toward
knowing why the gene breaks apart and how it
translocates to other genes.
“Our lab is trying to figure out what MLL
does in both healthy cells and in leukemia,”
says Dr. Guest. “When it does break apart
and translocates to another gene, what are
the resulting changes in the makeup of the
resulting proteins? We think that probably
changes how all of the DNA gets expressed.”
Sorting this out is a challenge. The MLL gene
triggers the production of the MLL protein,
which influences other genes to be turned on
or turned off. The MLL protein, in turn, can
attach itself to others in a protein complex
with impacts on many other genes. Finally,
what triggers the translocations and the
results of that will need to be understood.

The research currently focuses on established
leukemia cell lines. These cell lines provide
a model to study how MLL functions in living
cells. It is hoped that soon the research will
be able to study bone marrow cells from
Children’s Mercy patients.
“We need to understand what changes brought
about by MLL and associated proteins may
lead to this type of leukemia developing,” says
Dr. Guest. “It may then be possible to identify
molecular targets for drug development that
might work well for these infant patients.”

Just understanding
the genetic code
may not be enough
to really know
exactly what makes
leukemia tick.

This is an especially important goal given
the grim prognosis that currently accompanies
a leukemia diagnosis with MLL involvement
in infants.
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Reformulating Cancer Drugs for Children
Two years ago, Kathleen A. Neville, MD, MS, was asked to assume
the job of Director of the Experimental Therapeutics in Pediatric
Cancer Program (ETPC) at Children’s Mercy. The goal was to give
children with refractory cancer a local option to pursue treatment
with early phase cancer drugs. Since that time, the program has
grown in both size and stature and is involved in more than 15
studies of Phase I and Phase II agents.
“We are working with national consortia and have our own
investigator-initiated trials,” says Dr. Neville. “We also collaborate
closely with the Institute for Advancing Medical Innovation at
the University of Kansas. The collaboration’s main focus is
to reformulate older cancer drugs into pediatric-appropriate
formulations, as well as to perform drug discovery work relevant to
pediatric tumors.”
The program was selected to serve as the clinical pharmacology
core for The Pediatric Oncology Experimental Therapeutics
Investigators’ Consortium (POETIC) and the Neuroblastoma
Medulloblastoma Treatment Research Consortium.
“When those consortia begin designing a new trial, they look to us
for expertise analyzing the pharmacokinetics of a drug, providing
mathematical models on how the drug is handled by the body, and

helping design the types of observations needed to measure the
drug,” she says. “We are dealing with early phase agents and there
is not a lot of information available, so we are integrally involved
in making sure studies are designed appropriately in order to
determine whether a drug is safe and effective before it enters a
child’s body.”
Dr. Neville is board certified in hematology/oncology and
pharmacology, a relatively rare combination. The program’s other
staff includes Keith August, MD, MSc, Associate Director of the
Phase I program, nurse practitioners and research nurses who are
also experienced in treating pediatric cancer patients. For trials in
children, especially those trials that are focused on treatment in
addition to research, there is no other place with the expertise of
ETPC in the area.
Dr. Neville says, “For most of our kids, they have run out of
standard treatment options and the only remaining choices are
treatment with early phase therapy or hospice care. Children’s
Mercy felt that while contributing to the knowledge was important,
giving choices to our patients to be able to pursue treatment and
remain close to home was even more so. We are pretty far along in
achieving that goal.”

The collaboration’s main focus is to reformulate older cancer drugs into pediatric-appropriate
formulations as well as to perform drug discovery work relevant to pediatric tumors.
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Jignesh Dalal, MD

Alleviating Side Effects of Bone Marrow
Transplants with Photopheresis Therapy
For the past decade, Jignesh Dalal, MD, has worked to perfect a widely
used therapy that reduces bone marrow rejection, making it safe for
children.
In 2011, supported by a $120,000 grant from the Midwest Cancer Alliance,
Dr. Dalal and his colleagues designed photopheresis for pediatric patients
for treatment of graft-versus-host disease. To date, they have completed this
therapy in many patients, demonstrating photopheresis can be tolerated in
children.
“We’ve shown we can successfully do this in children,” says Dr. Dalal,
Associate Division Director, Bone Marrow Transplantation Section. “Taking
blood out of a child’s body can be dangerous. But we’ve done it and
alleviated the difficult side effects that come with a bone marrow transplant.”
After mixing a bowl of blood with psoralen, they expose cells to ultraviolet
light, killing reactive lymphocytes. Then, they infuse the blood back in to
help generate tolerance. The machine designed for children uses a smaller
bowl and circuit size, decreasing the time blood is outside the body.

get to know: Jignesh Dalal, MD
Associate Division Director, Section of Bone Marrow Transplantation;
Associate Professor of Pediatrics, University of Missouri–Kansas City School
of Medicine
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After the procedure, Dr. Dalal and his colleagues
monitor patients very closely. For two months posttransplant, they check in with patients twice a week.
The frequency falls to twice every 15 days for the
following six months.

Understanding how cells generate tolerance has
broader-reaching implications. With this knowledge
our team could ultimately reduce rejection rates for
solid organ transplants or improve treatments for
lupus and scleroderma.

During this time, our research team monitors B-cells
and T-cells at two-month, four-month and six-month
intervals. Doing so helps them determine how the
body generates tolerance and which immune system
cells play the biggest roles in the process. If the
cells are imbalanced, putting a child at risk for graftversus-host disease, the team attempts to push
them back into equilibrium.

The result of our team’s work is a significant step
forward. Successful photopheresis eliminates
the need for immune-suppressive drugs, making
children less vulnerable to viral, fungal or bacterial
infections that can attack their comprised immune
systems.

So far, Dr. Dalal says, the results have been very
encouraging.
According to Dr. Dalal, between 50 percent and 60
percent of patients experience positive benefits,
including increased energy, skin loosening,
decreased eye and mouth dryness, and an overall
improved quality of life.
“We’re seeing the positive effect of the
photopheresis appear between four to six weeks
after transplant, and the peak benefit comes at
around four to six months,” Dr. Dalal says. “From
what we’ve seen, that positive effect remains.”

In addition, the team is currently analyzing
data for its next challenge – understanding the
chemotherapy drug cyclophosphamide.
“This drug isn’t well understood. Currently, we give
all patients the same dosage,” Dr. Dalal says.
“At Children’s Mercy Hospital, we’re investigating
whether genes play a role in how the body
metabolizes it and if different doses produce
different side effects and desirable effects.”

Successful photopheresis
eliminates the need for
immune-suppressive drugs,
making children less vulnerable
to viral, fungal or bacterial
infections that can attack their
comprised immune systems.

This continued research strengthens Children’s
Mercy’s existing reputation as a world-class
pediatric cancer facility bringing cutting-edge
therapies to patients.
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Joy Fulbright, MD

AYA Program Focuses on
Improving Outcomes for
Adolescents and Adults
Every year about 26,000 patients between the ages of 15 and
29 are diagnosed with cancer in the United States and Canada.
Unfortunately, outcomes for patients in this age range are not
as good as younger patients with the same diagnoses. And,
for patients in this age range who are not seen at a children’s
hospital, the outcomes are even worse.
“There has been a lack of improvement in survival in this age
group when compared to patients in other age groups,” says Joy
Fulbright, MD, Pediatric Hematologist/Oncologist, and Assistant
Professor of Pediatrics. “That lack in improvement is thought to
be due to several key issues including low enrollment in clinical
trials, lack of appropriate psychosocial support, differences
in disease biology, and increased rates of non-compliance to
prescribed therapy.”

get to know: Joy Fulbright, MD
Pediatric Hematology/Oncology; Assistant
Professor of Pediatrics, University of
Missouri–Kansas City School of Medicine
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Dr. Fulbright is leading the development of an Adolescent and Young Adult
(AYA) cancer program at Children’s Mercy to address these issues.
Access to clinical trials is one of the highest priorities. In the United
States, approximately 10 percent of patients ages 15-19 and 1-2 percent
of patients ages 20-39 are enrolled in clinical trials, while 40-70 percent of
patients under age 15 are enrolled in clinical trials.
For example, from 2000-09, Children’s Mercy saw 194 new oncology
patients between the ages of 15-24 versus 1,032 new patients in that
age group within the hospital’s Missouri region (KC metro/Northwest/
Southwest) who were seen elsewhere. Thus, almost 80 percent of the
patients in the region are not being seen in a center where they could enroll
in or follow Children’s Oncology Group protocols.
“In certain cancers such as ALL, AML and Ewing’s Sarcoma, research has
shown that patients treated at a children’s hospital have better outcomes,”
says Dr. Fulbright. “Patients with certain diagnoses do better when following
the pediatric protocols, which in general are more aggressive.”
A study conducted by Gupta, Pappo, Saunders, et. al. looking at patients
treated with Ewing’s Sarcoma (EWS) showed that those treated at pediatric
facilities had better outcomes than those treated at adult facilities. The
three-year-event-free survival (EFS) for localized EWS was 43 percent in
those treated at adult facilities versus 70 percent in those treated at
the pediatric facility. Multiple studies comparing AYA patients with acute
lymphoblastic leukemia treated on pediatric versus adult protocols have
demonstrated improved survival in the patients treated on pediatric
protocols.

“The main issue is that patients in this age group don’t get enrolled. The
decreased enrollment has not allowed this population to experience the
same improvements in survival as the younger population or those patients
older than 40,” says Dr. Fulbright. Children’s Mercy is the only COG provider
in a 200-mile radius, meaning that access to COG trials and protocols is
limited outside of Kansas City. “Our goal is to develop research specifically
to improve adolescent and young adult care and increase participation in
COG trials.”
Dr. Fulbright received a Hyundai Hope on Wheels grant to help support the
development of the program. In addition to providing access to trials, the
program will focus on increasing awareness of the unique needs of AYA
patients, improving compliance with treatment regimens and follow-up care,
and addressing the psychosocial, educational and occupational needs of
patients on and off treatment to improve overall quality of life. Dr. Fulbright
also has a special research interest in decreasing risk of infertility for these
patients and improving medication compliance. Through a collaborative
effort at Children’s Mercy, smart phone apps are being designed to
improve drug compliance which we plan on studying in AYA patients on oral
chemotherapy regimens.
“We want to make sure they know these clinical trials are available and
to allow other hospitals, if they don’t have protocols for this age group, to
collaborate with us,” says Dr. Fulbright.
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The comprehensive cancer center at Children’s Mercy has an emphasis on clinical innovation and patientcentered care that depends on several different departments and areas of the hospital working together to
meet the needs of our patients. When a patient receives a cancer diagnosis, he or she has access to a multidisciplinary support staff that includes:
ii Pharmacy Department
ii Family Care Team (FaCt) that includes Child Life, Social Work, Chaplaincy and our Parent to Parent
Program
ii Survive and Thrive Program
ii Research and Data Management
Learn more about each of these programs and departments in the pages to follow as well as at
childrensmercy.org/oncology.

Pharmacy
The Pharmacy department is integral to the complete care of oncology patients. The Children’s Mercy
Pharmacy staff and facilities have evolved over the past decade with a goal of providing the best
pharmaceutical care possible for all our patients, including those with cancer.
The distinct teams within this department include decentralized pharmacists, clinical specialist pharmacists,
investigational drug service, home care and outpatient operations. We have two clinical pharmacy specialists
who work with patient families and assist the primary team in optimizing patient medications based on drug
interactions, disease states and organ function.
In addition to our pharmacy specialists, we have four pharmacists and a technician who are dedicated to the
review of chemotherapy orders, and responsible for the safe production and distribution of chemotherapy to
all patients within the Children’s Mercy system. These additional pharmacists may also spend part of their
day educating patient families and/or participating in patient care team activities. Our investigational drug
service works with more than 100 open drug trials for our patients including phase I and II oncology drug
studies. Our outpatient pharmacy is able to compound many prescriptions that are not commercially available.
Our Hematology/Oncology pharmacists are dedicated to providing education to pharmacy students through
clinical rotations and lectures at our local school of pharmacy and our pharmacy department has two
nationally accredited post-graduate residency programs. In 2008, Children’s Mercy started only the second
program in the nation for post-graduate residency training of pediatric hematology/oncology pharmacists,
providing pharmacists with focused and intensive training in the care of pediatric patients with cancers.
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Family Care Team (FaCT)
Music therapy services are offered to patients and families
at bedside to address the specific needs of each individual.
Music interventions are designed and planned after an
assessment of need and generally involve the use of both
live vocal and instrumental music. Children are encouraged to
take an active role in making music.
The Parent to Parent Program has been working hard to
continue providing for our families. There are many services
offered through the PTP program, including: trained parent
mentors available to share, listen and support our current
parents; a stocked parent room that offers weekly dinners,
breakfasts, therapeutic activities and a safe place to unwind
while a child is an inpatient; “care bags” for the new families
upon admission to help ease some burden of a hospital stay.
Child Life Specialists help make the hospital more
comfortable, easier to understand and fun for patients and
families. Child Life tries to reduce the stress and worry that
may come with being in the hospital or from being ill. The
trained specialists prepare patients and families for upcoming
procedures and help them through the procedures using
distraction and comfort positioning. They also empower the
patients by giving them realistic choices when choices are
available. Child Life helps the patients cope with their feelings,
thoughts and questions as well as learn and grow while still in
the hospital through normal developmental play and medical
play.
Ten clinical social workers are a part of the primary team
working with patients and their families diagnosed with any
form of cancer, including NHL. The social workers understand
that any change in a child’s health can alter a family’s life in

many ways. Social workers are licensed professionals trained
to address the needs of the patient and their family. Social
workers help with therapeutic support including adjustment
to illness, bereavement, crisis intervention, parent child
interactions and sibling support. Care planning including
education on advanced directives, school issues, legal issues
and transition to adult care are addressed as well. Finally,
social workers can assist with community referrals to assist
with financial concerns, transportation issues and mental
health referrals. The social workers help the family develop
coping skills from the point of diagnosis through the end of
treatment and beyond.
The chaplain working with Hematology/Oncology is available
to meet every new patient and family who are inpatients. The
family’s own clergy will be contacted if requested. Chaplains
can also assist with locating a local clergy person of their
denomination or faith for families outside the area. The
chaplain continues to support families throughout treatment.
A pair of psychologists assist with the mental health
challenges that present when under treatment for NHL or any
type of cancer. They are available to meet individually with the
patients and their families. The psychologists also complete
neurocognitive testing to aid patients in making sure their
educational needs are met.
An on-site teacher works with patients on the inpatient floor
and in clinic to assist with the challenge of keeping up with
school work while a patient is undergoing treatment. Our
school teacher is able to communicate directly with the child’s
school to get current assignments and also to advocate for
the patient’s needs once they return to the school setting.
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Survive and Thrive Program
The Survive and Thrive Program is available for any patient who is five years off
of active treatment. This program offers specialized services for childhood cancer
survivors. The focus of the program is comprehensive medical and emotional care
along with education on the late effects of childhood cancer therapy, necessary
recommendations for ongoing health care follow-up and healthy lifestyle choices.

Research and Data Management
The backbone of clinical research in pediatric cancer is the Children’s Oncology Group
(COG). Through this member organization, more than 200 institutions throughout the
world are able to open multi-site clinical trials and enroll the numbers of children
necessary to reach the answers to questions about treatment, supportive care and
follow-up care of children with cancer.
At Children’s Mercy, a dedicated research staff within the Division of Hematology
Oncology and Experimental Therapeutics coordinate the studies that enroll children
with non--Hodgkin lymphoma.
Besides the COG treatment studies that continue to adjust treatment regimens that
get the highest cure rate along with the fewest side effects, children with NHL can
participate in a national registry that is available for future contact by researchers,
biology studies that bank tumor specimens for scientists to study, and new drug
studies available through COG or other channels. Increasingly, Children’s Mercy
researchers are developing their own studies for our patients.
It is the goal of these researchers to provide families with quality research
opportunities led by quality research professionals.
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of Pediatrics
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Hematology/Oncology; Associate Director,
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Director, Leukemia Lymphoma Program; Assistant
Professor of Pediatrics

Anne M. Elliott, MD
Hematology/Oncology; Assistant Professor of
Pediatrics

Tristan G. Flatt, DO
Hematology/Oncology; Assistant Professor of
Pediatrics

Joy M. Fulbright, MD

Ram Kalpatthi, MD

Karen Lewing, MD
Fellowship Program Director, Hematology/Oncology;
Assistant Professor of Pediatrics

Michelle Manalang, MD
Hematology/Oncology; Director, Liver Tumor
Program; Assistant Professor of Pediatrics

Doug Myers, MD
Hematology/Oncology; Associate Professor of
Pediatrics

Mohamed Radhi, MD
Hematology/Oncology; Associate Professor of
Pediatrics

Hematology/Oncology; Director, Adolescent
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Programs; Assistant Professor of Pediatrics

Kristie L. Sabol, DO

Kevin F. Ginn, MD

Mukta Sharma, MD, MPH

Hospitalist in Hematology/Oncology; Assistant
Professor of Pediatrics

Hematology/Oncology; Neuro-Oncologist; Director,
Brain Tumor Program; Assistant Professor of
Pediatrics

Hematology/Oncology; Assistant Professor of
Pediatrics

Erin M. Guest, MD

Director, Hemophilia/Coagulation/Thrombosis
Program; Hematology/Oncology; Associate
Professor of Pediatrics

Hematology/Oncology; Assistant Professor of
Pediatrics
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REDEFINING PEDIATRIC MEDICINE ONE CHILD AT A TIME

Ranked one of the “Best Children’s Hospitals” in cancer by U.S. News & World Report.

